Managing Side Effects of Newer Therapies for Acute Lymphoblastic Leukemia (ALL)
Treatment of Ph+ Relapsed/Refractory ALL
Treatment of Ph- Relapsed/Refractory ALL
Reducing the Risk of Severe Illness for Patients With COVID-19
Webinar | 0.75 - 45 mins | Interactive Case | Rheumatology | Biosimilars | BiosimilarsCME.org | Online |
A ACCME Accredited provider.
The France Foundation ©
Chandler Building, 84 Lyme Street, Old Lyme, CT USA